Continuation, CIP and divisional applications

The three kinds of continuing application

35 U.S.C. 120 gives a later application "the same effect, as to such invention, as though filed on the date of the prior application" if the invention was disclosed in the prior application in the manner section 112(a) requires, the two share an inventor, the later one is filed while the earlier is pending, and it contains a specific reference to the earlier one. The MPEP defines the three kinds (MPEP 201.06 to 201.08):

• Continuation: an application for an invention disclosed in a copending prior application. The disclosure must not include anything that would be new matter if added to the parent by amendment. In practice the specification and drawings are copied and only the claims change.
• Divisional: an application for an independent or distinct invention carved out of the parent, again with no new matter. It is often filed after a restriction requirement under 35 U.S.C. 121, which forced you to elect one invention in the parent.
• Continuation-in-part (CIP): an application filed during the life of the parent that repeats some substantial portion or all of it and adds matter the parent did not disclose. A CIP must be filed under 37 CFR 1.53(b); it cannot be a continued prosecution application.

The benefit is decided claim by claim. A claim in any continuing application gets the parent's date only if the parent supports it under section 112(a) (MPEP 211.05). This matters most for CIPs: a claim that needs the new matter is dated from the CIP, and the parent's own publication, if more than a year old, can be prior art against it.

Continuation vs CIP vs divisional

A continuing application is not the same as a request for continued examination (RCE). An RCE under 37 CFR 1.114 reopens prosecution in the same application after a final rejection; a continuation is a new application with its own number and its own examination. See responding to a USPTO office action for the RCE route.

Copendency and the benefit claim

The child must be filed before the parent is patented, abandoned or terminated. If the parent issues, filing on the same day as the issue date is still in time (MPEP 211.01(b), citing Immersion v. HTC). A grandchild can claim back to the first application through an unbroken chain, as long as each link was copending with the one before it.

Three moments catch people out:

• After allowance. Once the issue fee is paid, the patent issues within weeks. Decide on continuations when the notice of allowance arrives, and file before or with the issue fee if you want to be safe.
• After a final rejection. If you let the parent go abandoned, file the continuation before the response period, as extended, runs out.
• During an appeal. A parent on appeal is still pending, so file any continuation while the appeal runs rather than waiting for the outcome.

The benefit claim goes in the application data sheet, naming each prior application by number and stating whether the new one is a continuation, divisional or continuation-in-part (37 CFR 1.78(d)(2)). It must be presented within the later of 4 months from the child's filing date and 16 months from the parent's, together with any continuing application fee due (1.78(d)(3)). Otherwise the benefit is waived and can only be recovered by a petition under 1.78(e). Check the filing receipt: the USPTO says an entered benefit claim appears there under domestic priority data.

Design applications have one extra route. A design continuation or divisional (not a CIP) can be filed as a continued prosecution application under 37 CFR 1.53(d), by a simple request in the parent design application. See the design patent guide.

Patent term of continuing applications

A continuing application does not buy more time. Under 35 U.S.C. 154(a)(2), the term ends 20 years from the filing date of the earliest application referenced under section 120, 121, 365(c) or 386(c). That applies to CIP claims to new matter too: they get the CIP's date for prior art but the parent's date for expiry. Each child can earn its own patent term adjustment for USPTO delay in that application, but no adjustment can run past the date set in a terminal disclaimer (154(b)(2)(B)). Maintenance fees run from each patent's own grant date (37 CFR 1.362(c)(3)).

Double patenting and terminal disclaimers

Because a family shares one disclosure, examiners routinely check whether the child's claims are patentably distinct from the parent's. There are two kinds of double patenting (MPEP 804):

• Statutory ("same invention"), based on section 101: two claims of identical scope. A terminal disclaimer cannot cure it. You must amend or cancel one of the claims.
• Nonstatutory (obviousness-type): the child's claim is an obvious variation of a claim in the parent or another family member. It is cured by arguing the claims are distinct or by filing a terminal disclaimer.

A terminal disclaimer under 37 CFR 1.321(c) gives up any term past the expiry of the reference patent and makes the child enforceable only while it is commonly owned with it. The fee is $183 with no entity discount (37 CFR 1.20(d)). Within a family the term cost is usually small, since everything expires on the same base date anyway; what you lose is patent term adjustment beyond that date, and the freedom to sell the patents separately. A 2024 USPTO proposal to make disclaimed patents unenforceable if a linked patent fell to prior art was withdrawn on December 4, 2024. No replacement has been proposed as of October 26, 2026.

The divisional safe harbor

The third sentence of section 121 bars using a patent from a restricted application, or from an application filed as a result of the restriction, against a divisional filed before that patent issues. So a divisional prosecuting claims the examiner restricted out does not need a terminal disclaimer against its parent. The shield is narrow (MPEP 804.01): it does not cover a voluntary divisional filed without a restriction requirement, and it is lost if the divisional's claims drift back toward the elected invention. Continuations and CIPs never get it.

Two Federal Circuit decisions to know

• In re Cellect (August 28, 2023): obviousness-type double patenting is judged on each patent's expiry date after patent term adjustment is added. A family member that earned more adjustment than a related patent can be held invalid over it. Check adjustment across a family before deciding whether to file terminal disclaimers.
• Allergan v. MSN Laboratories (August 13, 2024): a first-filed, first-issued claim cannot be invalidated for double patenting by a later-filed, later-issued claim in the same family with a common priority date, even if the later patent expires earlier. The parent with adjustment is protected against its own children.

The continuing application fee (2025 rule)

The FY 2025 fee rule (89 FR 91898) added a surcharge for late continuing applications from January 19, 2025. It is in 37 CFR 1.17(w), and on the current USPTO fee schedule as fee codes 1055 and 1056:

How it works, from the USPTO's quick reference guide to the continuing application fee:

• It applies to utility, plant and design continuations, divisionals and CIPs, including national stage and reissue applications that are continuing applications.
• The earliest benefit date is the earliest date claimed under section 120, 121, 365(c) or 386(c). Provisional and foreign priority dates are ignored.
• The fee is part of the benefit claim. If it is not paid when the claim is presented, the whole benefit claim is not entered.
• It is charged once per application, by date bracket; the 9-year fee is reduced by any 6-year fee already paid.

Status as of October 26, 2026: the amounts are unchanged since January 19, 2025, and a search of the Federal Register shows no USPTO rule or proposed rule since then that changes the fee or adds another continuation surcharge (only a January 14, 2025 notice correcting typographical errors in the fee rule). The practical effect is to reward filing continuations early in a family's life, rather than keeping one alive by serial filings late in the term.

Continuation strategy

• Take the allowable claims, keep fighting. When the examiner allows narrow claims and rejects broad ones, accept the narrow patent now and pursue the broad claims in a continuation. You get an enforceable patent sooner.
• Keep one application pending. A pending continuation lets you write claims later that read on a competitor's product, as long as the original disclosure supports them. File the next one before the current one issues. With the continuing application fee, do this within the first 6 years where you can.
• Divide claim types. Method, system and medium claims, or claims aimed at different parts of the supply chain, can go in separate applications so each gets focused examination.
• Use divisionals for restricted inventions. File them while the parent is pending to keep the section 121 safe harbor, and keep their claims consonant with the restriction.
• Use CIPs sparingly. An improvement often deserves its own application. A CIP gives new matter only the CIP's date while the term still runs from the parent, so you trade term for little.
• Mind the cost of a family. Each child pays full filing, search, examination, issue and maintenance fees. Prune the family when the claims stop being commercially useful.

Continuations work only as well as the original disclosure. A specification with many embodiments, fallback features and clear definitions supports more claims later. Our guides on how to write patent claims, the utility patent, the nonprovisional application and the provisional application cover building that foundation, and provisional vs nonprovisional explains how the first filings fit together.

More USPTO guides

• How to file a provisional patent application (US)

  What a US provisional must contain, the USPTO fees, the 12-month deadline under 35 U.S.C. 119(e), and when to skip it.

• USPTO patent fees (2026)

  Every USPTO patent fee for large, small and micro entities, from filing to maintenance, with a fee calculator.

• Patent drawing requirements: USPTO, EPO and India

  37 CFR 1.84, the EPO rules that replaced Rule 46 EPC, and Indian rule 15, compared side by side.

• How to write patent claims: USPTO, EPO and India

  Claim structure and worked examples, then the claim rules and fees at the USPTO, the EPO and the Indian Patent Office, side by side.

• How to respond to a USPTO office action

  Reply deadlines and extension fees, 101, 102, 103 and 112 rejections, interviews, and options after a final rejection.

• Types of patent searches, and which one you need

  Patentability, freedom-to-operate, invalidity and landscape searches compared by purpose, timing, scope and deliverable.

• Patentability search: how to check novelty before you file

  What counts as prior art under 35 U.S.C. 102 and Art. 54 EPC, the grace period gap, search steps and how to read results.

• Freedom-to-operate search in the US and Europe

  In-force claims only, legal status checks at the USPTO, EPO and UPC, FTO opinions after Halo, and design-arounds.

• Invalidity search: prior art to challenge a patent

  IPR, PGR, EPO opposition and UPC revocation deadlines, prior art dates, standards documents and claim charts.

• Patent landscape analysis, step by step

  Building a CPC and keyword dataset, cleaning families and names, the metrics that matter and the 18-month publication lag.

• How to use USPTO Patent Public Search

  Basic and Advanced Search, the three databases, field codes, ADJ, NEAR, WITH and SAME, truncation and a worked search.

• Google Patents search guide

  Search operators and fields, Boolean and proximity syntax, non-patent literature, and where Google Patents falls short of the official databases.

• The Cooperative Patent Classification (CPC), explained

  How CPC symbols are built, CPC against IPC, the Y section, how to find the right class and how to search it in each database.

• Patent search Boolean operators and search strings

  Boolean, proximity and truncation syntax compared across Patent Public Search, Espacenet, Google Patents and The Lens, with semantic search for contrast.

• How to respond to a 35 U.S.C. 101 rejection

  The Alice/Mayo steps in MPEP 2106, Ex parte Desjardins and the 2024-2026 USPTO guidance, Berkheimer evidence and Rule 132 eligibility declarations.

• How to respond to a 35 U.S.C. 102 rejection

  Anticipation under MPEP 2131, AIA 102(a)(1) and (a)(2), the 102(b) exceptions, inherency and Rule 130 declarations.

• How to respond to a 35 U.S.C. 103 rejection

  Graham and the KSR rationales in MPEP 2143, teaching away, motivation to combine, secondary considerations with nexus, and Rule 132 evidence.

• How to respond to a 35 U.S.C. 112 rejection

  Written description and enablement after Amgen, 112(b) indefiniteness, 112(f) means-plus-function after Williamson, and 112(d) dependent claims.

• The PCT application: timeline, fees and national phase

  The international phase month by month, receiving Office and ISA fees in CHF, USD and EUR, national phase deadlines by office, and a deadline calculator.

• Entering the US national stage under 35 U.S.C. 371

  The 30-month deadline and revival, the 371 requirements, national stage fees by entity size, and 371 versus a bypass continuation.

• The US foreign filing license (35 U.S.C. 184)

  When a US-made invention needs a license to be filed abroad, the six-month rule, expedited and retroactive licenses, and the Indian and European equivalents.

• Filing a US patent from Europe or India

  The 2026 US practitioner rule for foreign applicants, Paris priority and certified copies, small entity status, PCT or direct, fees and translations.

• What is a utility patent?

  What a US utility patent covers under 35 U.S.C. 101, the parts of the application in 37 CFR 1.77 order, the 20-year term and USPTO costs.

• Design patents in the United States

  What a design patent protects, drawings and the single claim, the 15-year term, Hague filings, LKQ v. GM, and design vs utility patents.

• How to file a nonprovisional patent application

  Required parts and fees, claiming a provisional within 12 months, DOCX filing in Patent Center, and what happens after you file.

• Provisional vs nonprovisional patent application

  The two US filings side by side, the cost of each route, the effect on term and publication, and a guide to which to file.

• How much does a patent cost?

  USPTO fees by entity size from filing to the last maintenance fee, what drives professional fees, EPO fees, and an estimator.

• How to patent an idea in the US

  Nine steps from patentability and search to provisional filing, Patent Center, examination and maintenance, with the USPTO's free help programs.

• Small entity vs micro entity status

  Who qualifies under 37 CFR 1.27 and 1.29, the 2026 income limit, SB/15A and SB/15B, license traps, fixing errors, and an eligibility checker.

• How long does a patent last?

  US utility and design terms, patent term adjustment and extension, terminal disclaimers, maintenance fee deadlines, Europe and India, with an expiry estimator.

• Can AI write a patent application?

  What AI drafting does well and badly, the USPTO and EPO positions on AI tools, AI inventorship after 2025, and confidentiality.

• Restriction requirements and election of species

  How to answer a USPTO restriction or election of species requirement, from traverse and rejoinder to divisionals and unity in 371 cases.

• Options after a final rejection

  Amendment after final, advisory actions, the end of AFCP 2.0, RCE, pre-appeal and appeal, with fees, timing and USPTO outcome data.

• Request for continued examination (RCE)

  What 37 CFR 1.114 requires, first and later RCE fees, patent term effects, and when an RCE beats an appeal.

• Information disclosure statements (IDS)

  The duty of disclosure, IDS timing windows and fees, the 2025 size fee, EPO search reports, Therasense and QPIDS.

• PTAB ex parte appeals

  Notice of appeal to decision step by step, with fees, deadlines and the PTAB's FY 2026 pendency and outcome statistics.

• Track One prioritized examination

  Track One requirements, fees by entity size, the 20,000 annual cap and USPTO timing data, plus PPH and age or health petitions.

• 35 U.S.C., annotated: US patent law section by section

  The current text of 34 key sections of Title 35 with plain-English summaries, key cases, 37 CFR rules and MPEP references.

All guides, by patent office